BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 32235172)

  • 1. Brief Report: Relationship Between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease in Persons With HIV.
    Kaplan A; Simon TG; Henson JB; Wang T; Zheng H; Osganian SA; Rosenblatt R; Lake J; Corey KE
    J Acquir Immune Defic Syndr; 2020 Aug; 84(4):400-404. PubMed ID: 32235172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular disease in adult patients with type 1 diabetes.
    Mantovani A; Mingolla L; Rigolon R; Pichiri I; Cavalieri V; Zoppini G; Lippi G; Bonora E; Targher G
    Int J Cardiol; 2016 Dec; 225():387-391. PubMed ID: 27768965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonalcoholic Fatty Liver Disease and the Development of Metabolic Comorbid Conditions in Patients With Human Immunodeficiency Virus Infection.
    Krahn T; Martel M; Sapir-Pichhadze R; Kronfli N; Falutz J; Guaraldi G; Lebouche B; Klein MB; Wong P; Deschenes M; Ghali P; Sebastiani G
    J Infect Dis; 2020 Aug; 222(5):787-797. PubMed ID: 32249283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Food Insecurity on Hepatic Steatosis and Fibrosis in People With HIV.
    Kardashian A; Lloyd A; Vilar-Gomez E; Naggie S; Sulkowski MS; Woreta T; Lake JE; Crandall H; Loomba R; Wilson LA; Sterling RK; Heath S; Gawrieh S; Chalasani NP; Price JC;
    Clin Gastroenterol Hepatol; 2024 Jul; 22(7):1427-1435.e6. PubMed ID: 38582290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonalcoholic Fatty Liver Disease (NAFLD)-A New Cardiovascular Risk Factor in Peritoneal Dialysis Patients.
    Mikolasevic I; Milic S; Racki S; Zaputovic L; Stimac D; Radic M; Markic D; Orlic L
    Perit Dial Int; 2016; 36(4):427-32. PubMed ID: 26475841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Burden of fatty liver and hepatic fibrosis in persons with HIV: A diverse cross-sectional US multicenter study.
    Gawrieh S; Lake JE; Debroy P; Sjoquist JA; Robison M; Tann M; Akisik F; Bhamidipalli SS; Saha CK; Zachary K; Robbins GK; Gupta SK; Chung RT; Chalasani N; Corey KE
    Hepatology; 2023 Aug; 78(2):578-591. PubMed ID: 36805976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study.
    Lee H; Lee YH; Kim SU; Kim HC
    Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2138-2147.e10. PubMed ID: 33348045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic steatosis and nonalcoholic fatty liver disease are common and associated with cardiometabolic risk in a primary prevention cohort of people with HIV.
    Lake JE; Taron J; Ribaudo HJ; Leon-Cruz J; Utay NS; Swaminathan S; Fitch KV; Kileel EM; Paradis K; Fulda ES; Ho KS; Luetkemeyer AF; Johnston CD; Zanni MV; Douglas PS; Grinspoon SK; Lu MT; Fichtenbaum CJ;
    AIDS; 2023 Nov; 37(14):2149-2159. PubMed ID: 37503623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of Cardiovascular Disease in Individuals With Nonobese Nonalcoholic Fatty Liver Disease.
    Arvind A; Henson JB; Osganian SA; Nath C; Steinhagen LM; Memel ZN; Donovan A; Balogun O; Chung RT; Simon TG; Corey KE
    Hepatol Commun; 2022 Feb; 6(2):309-319. PubMed ID: 34558862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fatty liver index and development of cardiovascular disease in Koreans without pre-existing myocardial infarction and ischemic stroke: a large population-based study.
    Kim JH; Moon JS; Byun SJ; Lee JH; Kang DR; Sung KC; Kim JY; Huh JH
    Cardiovasc Diabetol; 2020 May; 19(1):51. PubMed ID: 32359355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches.
    Dongiovanni P; Paolini E; Corsini A; Sirtori CR; Ruscica M
    Eur J Clin Invest; 2021 Jul; 51(7):e13519. PubMed ID: 33583033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alcohol Use and Cardiovascular Disease Risk in Patients With Nonalcoholic Fatty Liver Disease.
    VanWagner LB; Ning H; Allen NB; Ajmera V; Lewis CE; Carr JJ; Lloyd-Jones DM; Terrault NA; Siddique J
    Gastroenterology; 2017 Nov; 153(5):1260-1272.e3. PubMed ID: 28802566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Skeletal muscle mass and abdominal obesity are independent predictors of hepatic steatosis and interact to predict ten-year cardiovascular disease incidence: Data from the ATTICA cohort study.
    Kouvari M; Polyzos SA; Chrysohoou C; Skoumas J; Pitsavos CS; Panagiotakos DB; Mantzoros CS
    Clin Nutr; 2022 Jun; 41(6):1281-1289. PubMed ID: 35504171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expert Panel Review on Nonalcoholic Fatty Liver Disease in Persons With Human Immunodeficiency Virus.
    Lake JE; Overton T; Naggie S; Sulkowski M; Loomba R; Kleiner DE; Price JC; Chew KW; Chung RT; Corey KE
    Clin Gastroenterol Hepatol; 2022 Feb; 20(2):256-268. PubMed ID: 33069882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular risk factors in non-alcoholic fatty liver disease.
    Hagström H; Nasr P; Ekstedt M; Hammar U; Stål P; Askling J; Hultcrantz R; Kechagias S
    Liver Int; 2019 Jan; 39(1):197-204. PubMed ID: 30253056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonalcoholic Fatty Liver Disease, Liver Fibrosis and Cardiovascular Disease in the Adult US Population.
    Ciardullo S; Cannistraci R; Mazzetti S; Mortara A; Perseghin G
    Front Endocrinol (Lausanne); 2021; 12():711484. PubMed ID: 34381424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased prevalence of cardiovascular disease in Type 1 diabetic patients with non-alcoholic fatty liver disease.
    Targher G; Pichiri I; Zoppini G; Trombetta M; Bonora E
    J Endocrinol Invest; 2012 May; 35(5):535-40. PubMed ID: 21795844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histological severity of nonalcoholic fatty liver disease is associated with 10-year risk for atherosclerotic cardiovascular disease.
    Park JH; Koo BK; Kim W; Kim WH;
    Hepatol Int; 2021 Oct; 15(5):1148-1159. PubMed ID: 34081289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coffee consumption is not associated with prevalent subclinical cardiovascular disease (CVD) or the risk of CVD events, in nonalcoholic fatty liver disease: results from the multi-ethnic study of atherosclerosis.
    Simon TG; Trejo MEP; Zeb I; Frazier-Wood AC; McClelland RL; Chung RT; Budoff MJ
    Metabolism; 2017 Oct; 75():1-5. PubMed ID: 28964324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fatty Liver Index as a proxy for non-alcoholic fatty liver disease and the risk of stroke and coronary heart disease: The Suita Study.
    Arafa A; Kashima R; Matsumoto C; Kokubo Y
    J Stroke Cerebrovasc Dis; 2024 Jan; 33(1):107495. PubMed ID: 38000108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.